• +1-646-491-9876
    • +91-20-67278686

    Search

    Bile Duct Cancer Pipeline Review H1 2017

    Bile Duct Cancer Pipeline Review H1 2017

    • Report Code ID: RW0001858679
    • Category Pharmaceuticals
    • No. of Pages 609
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

    Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen) , loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 51, 21, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

    Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Bile Duct Cancer (Cholangiocarcinoma) - Overview 7
    Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development 8
    Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 22
    Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 36
    Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles 70
    Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 584
    Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 586
    Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 587
    Appendix 598

    List of Tables

    Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corp, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corp, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CytomX Therapeutics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison China MediTech Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ignyta Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Immodulon Therapeutics Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Immunitor Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Insys Therapeutics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ipsen SA, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Leap Therapeutics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sirnaomics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Advenchen Laboratories LLC
    Agios Pharmaceuticals Inc
    Ariad Pharmaceuticals Inc
    ArQule Inc
    Array BioPharma Inc
    Arrien Pharmaceuticals LLC
    Aslan Pharmaceuticals Pte Ltd
    AstraZeneca Plc
    Bavarian Nordic A/S
    Bayer AG
    BeiGene (Beijing) Co Ltd
    Blueprint Medicines Corp
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Celgene Corp
    CellAct Pharma GmbH
    Cellceutix Corp
    Cellular Biomedicine Group Inc
    Cornerstone Pharmaceuticals Inc
    CytomX Therapeutics Inc
    Delcath Systems Inc
    Eisai Co Ltd
    Eli Lilly and Company
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    H3 Biomedicine Inc
    Halozyme Therapeutics Inc
    Hutchison China MediTech Ltd
    Ignyta Inc
    Immodulon Therapeutics Ltd
    Immunitor Inc
    Incyte Corp
    Innopharmax Inc
    Insys Therapeutics Inc
    Ipsen SA
    Johnson & Johnson
    Komipharm International Co Ltd
    Leap Therapeutics Inc
    Loxo Oncology Inc
    Mebiopharm Co Ltd
    MedImmune LLC
    Merck & Co Inc
    NanoCarrier Co Ltd
    NormOxys Inc
    Novartis AG
    NuCana BioMed Ltd
    Oasmia Pharmaceutical AB
    OncoTherapy Science Inc
    Panacea Pharmaceuticals Inc
    PCI Biotech Holding ASA
    Pfizer Inc
    Pharma Mar SA
    Plexxikon Inc
    Provecs Medical GmbH
    Puma Biotechnology Inc
    RedHill Biopharma Ltd
    Sanofi
    Senhwa Biosciences Inc
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    Sirnaomics Inc
    Sun Pharma Advanced Research Company Ltd
    SynCore Biotechnology Co Ltd
    SyntheX Inc
    Taiwan Liposome Company Ltd
    tella Inc
    Threshold Pharmaceuticals Inc
    VasGene Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//bile-duct-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bile-duct-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bile-duct-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments